Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan monotherapy
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intperitoneal, Intravenous
01
Overview
Liposomal irinotecan monotherapy refers to the investigational intraperitoneal administration of liposomal irinotecan (specifically CSPC Pharmaceutical Group's generic formulation, Duoenyi/HE072) as a single agent. It is being evaluated in a Phase Ib/II clinical trial (NCT07397819) sponsored by Sun Yat-sen University (led by Dr. Dong sheng Zhang) in collaboration with CSPC Pharmaceutical Group for the treatment of malignant ascites (malignant peritoneal effusion) in patients who have failed prior standard therapy. Irinotecan is a camptothecin derivative that acts as a DNA topoisomerase 1 inhibitor, preventing the religation of single-strand DNA breaks and leading to double-strand DNA damage and cell death. The liposomal formulation (nanoliposomal drug delivery system) extends the circulation half-life and enhances tumor accumulation of the active drug.
- Brand names
- DoenyiDuoenyiOnivyde
- Other names
- irinotecan liposomalirinotecan liposomeliposomal irinotecannanoliposomal irinotecanpegylated liposomal irinotecan
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on liposomal irinotecan monotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan monotherapy.